Takeda Pharmaceutical Co Ltd
TKDA
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,152.30 | 268.20 | -2.85% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,790.65 | 847.35 | -3.44% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,473.41 | 306.70 | -2.85% |
| HKSE | 25,768.08 | 612.94 | -2.32% |
| NASDAQ | 22,516.69 | 232.17 | -1.02% |
| Nikkei 225 | 56,279.05 | 2,474.34 | -4.21% |
| NZX 50 Index | 13,559.63 | 111.08 | -0.81% |
| S&P 500 | 6,816.63 | 64.99 | -0.94% |
| S&P/ASX 200 | 8,935.40 | 246.30 | -2.68% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |